Technology
Health
Pharmaceutical

Aerpio Pharmaceuticals

$0.8297
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.0197 (2.43%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell ARPO and other stocks, options, ETFs, and crypto commission-free!

About ARPO

Aerpio Pharmaceuticals, Inc. Common Stock, also called Aerpio Pharmaceuticals, is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. Read More Its product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company was founded by Joseph H. Garder on November 17, 2011 and is headquartered in Cincinnati, OH.

Employees
27
Headquarters
Cincinnati, Ohio
Founded
Market Cap
32.88M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
92.38K
High Today
$0.8484
Low Today
$0.8001
Open Price
$0.82
Volume
51.11K
52 Week High
$4.30
52 Week Low
$0.75

Collections

Technology
Health
Pharmaceutical
Biopharmaceutical
Research And Development
Medical
2018 IPO
US

ARPO Earnings

-$0.23
-$0.22
-$0.22
-$0.21
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 5, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.